Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €241.45 EUR
Change Today +0.30 / 0.12%
Volume 3.7K
DIM On Other Exchanges
EN Paris
As of 11:35 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

sartorius stedim biotech (DIM) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/22/15 - €243.50
52 Week Low
10/16/14 - €120.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

sartorius stedim biotech (DIM) Related Businessweek News

No Related Businessweek News Found

sartorius stedim biotech (DIM) Details

Sartorius Stedim Biotech S.A. provides equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry worldwide. The company’s integrated solutions cover fermentation, filtration, purification, fluid management, and lab technologies that support the biopharmaceutical industry to develop and produce drugs. It provides various products, such as media for cell cultivation; bioreactors in various sizes for cell propagation; filters for purifying cell materials; systems for storage and transportation of finished products; and single-use bags for fermentation applications. The company also offers validation and consulting services, as well as equipment installation, maintenance, and repair services. It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. Sartorius Stedim Biotech S.A. was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.

3,700 Employees
Last Reported Date: 04/20/15
Founded in 1870

sartorius stedim biotech (DIM) Top Compensated Officers

Chairman of The Board and Chief Executive Off...
Total Annual Compensation: €1.0M
Executive Vice President of Operations & IT a...
Total Annual Compensation: €543.0K
Executive Vice President of Research & Develo...
Total Annual Compensation: €543.0K
Executive Vice President of Marketing Sales &...
Total Annual Compensation: €636.0K
Compensation as of Fiscal Year 2014.

sartorius stedim biotech (DIM) Key Developments

Sartorius Stedim Biotech S.A. Presents at Gilbert Dupont Healthcare conference, May-21-2015

Sartorius Stedim Biotech S.A. Presents at Gilbert Dupont Healthcare conference, May-21-2015 . Venue: Paris, France.

Sartorius Stedim Biotech S.A. Introduces Sartoclear Dynamics Clarification System

Sartorius Stedim Biotech S.A. has introduced Sartoclear Dynamics, a clarification system featuring new single-use technology for harvesting mammalian cell cultures with high cell densities. Sartorius Stedim Biotech has now developed this robust technology for biotech applications. Specially designed for cGMP processing, Sartoclear Dynamics consists of prefilled single-use bags containing ultrapure diatomaceous earth (DE) in a choice of 0.5 kg to 10 kg. With a new quick-connect adapter for dust-free powder transfer, DE can be directly mixed into the cell culture fluid. This porous filter aid prevents blockage of the Sartoclear Dynamics filters. As the system maintains a constant ratio of biomass and filter aid, users will benefit from continuous maximum filter performance. Consistent results, ease of use, tremendous speed and linear scalability are the key characteristics of the Sartoclear Dynamics technology. Used in combination with precipitation, this technology transforms harvesting from a two-stage process into a single-stage operation, saving valuable footprint - and time.

Sartorius Stedim Biotech S.A. Reports Earnings Results for the First Quarter of 2015

Sartorius Stedim Biotech S.A. reported earnings results for the first quarter of 2015. For the quarter, the company reported sales revenue of EUR 204.4 million against EUR 154.0 million a year ago. Earnings before interest & taxes were EUR 41.3 million against EUR 24.5 million a year ago. Profit before tax was EUR 27.5 million against EUR 22.0 million a year ago. Net profit for the period attributable to shareholders of the company was EUR 18.7 million or EUR 1.22 per basic and diluted share against EUR 15.6 million or EUR 1.01 per basic and diluted share a year ago. Net cash flow from operating activities was EUR 15.9 million against EUR 13.9 million a year ago. Capital expenditure were EUR 0.2 million against EUR 0.1 million a year ago. Net debt at the end of the first quarter was EUR 89.1 million. The company reported an over proportionate increase in earnings, mainly driven by economies of scale and favorable currency effects.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DIM:FP €241.45 EUR +0.30

DIM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Corning Inc $21.50 USD -0.32
General Electric Co $27.68 USD -0.04
Pall Corp $124.59 USD +0.30
Thermo Fisher Scientific Inc $132.15 USD -0.69
View Industry Companies

Industry Analysis


Industry Average

Valuation DIM Industry Range
Price/Earnings 50.3x
Price/Sales 5.2x
Price/Book 6.7x
Price/Cash Flow 50.4x
TEV/Sales 5.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SARTORIUS STEDIM BIOTECH, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at